Beyondspring Inc
Beyondspring Inc is a clinical-stage biopharmaceutical company focused on the development of immuno-oncology therapies.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Beyondspring's stock with a target price of $1.25, indicating modest growth potential.
Financial Health
Beyondspring Inc is showing modest cash flow, indicating stability but with room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BYSI
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketChina's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage pipeline
Trial readouts and regulatory progress are central to valuation; results can be binary and may cause significant share movement.
Potential catalysts
Upcoming study results, approvals or partnerships could change the outlook, though timings and outcomes are uncertain.
Small-cap dynamics
Lower market capitalisation can create higher volatility and liquidity constraints; suitable for investors who accept greater risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
